Related Experiment Videos
Average parameters as a trend to reduce the residual variability in bioequivalence trials
1Department of Pharmacology and Biopharmacy, Faculty of Chemistry, Montevideo, Uruguay.
European Journal of Drug Metabolism and Pharmacokinetics
|September 2, 1998
Summary
Traditional bioavailability and bioequivalence studies using Cmax and Tmax are unreliable for slow-release drugs and saliva samples. New parameters, average concentration (Cav) and average maximum concentration (Cmax,av), offer reduced variability for more accurate bioequivalence assessments.
Area of Science:
- Pharmacokinetics
- Drug formulation and delivery
- Analytical chemistry
Background:
- Bioavailability and bioequivalence (BA/BE) studies typically rely on maximum concentration (Cmax) and time to reach Cmax (Tmax).
- These parameters are often unsuitable for slow-release formulations and saliva-based pharmacokinetic trials due to complex drug concentration profiles and high variability.
- The inherent variability in Cmax can inflate residual variance in ANOVA, reducing statistical power and hindering bioequivalence conclusions.
Purpose of the Study:
- To propose alternative pharmacokinetic parameters for evaluating drug concentration-time curves in BA/BE studies.
- To address the limitations of Cmax and Tmax in slow-release formulations and saliva sampling.
- To introduce parameters that reduce residual variability in bioequivalence assessments.
Main Methods:
- Evaluation of drug concentration-time profiles from bioavailability and bioequivalence studies.
- Analysis of drug concentration data from slow-release formulations and saliva samples.
- Introduction and assessment of average concentration (Cav), average maximum concentration (Cmax,av), and %Cmax,av as potential BA/BE parameters.
Main Results:
- Standard Cmax and Tmax parameters are not advisable for slow-release drugs and saliva studies.
- Drug concentration profiles in these scenarios often exhibit multiple peaks, complicating Cmax/Tmax determination.
- The proposed parameters (Cav, Cmax,av, %Cmax,av) demonstrate a reduction in residual variability for bioequivalence studies.
Conclusions:
- Average concentration (Cav) and average maximum concentration (Cmax,av) are proposed as more robust metrics for BA/BE evaluations.
- These novel parameters can improve the reliability of bioequivalence studies, particularly for challenging formulations and biological fluids.
- Implementing Cav and Cmax,av can enhance the statistical power and accuracy of bioequivalence assessments.